What changed in Biomarin Pharmaceutical Inc's latest annual report
In the year ended 31 Dec 2025, Biomarin Pharmaceutical Inc's revenue rose 12.9% to USD 3.22bn, from USD 2.85bn; net income fell 18.3% to USD 348.90m, from USD 426.86m; cash and cash equivalents rose 39.1% to USD 1.31bn, from USD 942.84m.
Year ended 31 Dec 2025. Source: 10-K filed 26 Feb 2026, read it on SEC EDGAR.
USD 2.85bn to USD 3.22bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.85bn | 3.22bn | Up 12.9% |
| Net income | 426.86m | 348.90m | Down 18.3% |
| Total assets | 6.99bn | 7.59bn | Up 8.7% |
| Total liabilities | 1.33bn | 1.51bn | Up 13.2% |
| Cash and cash equivalents | 942.84m | 1.31bn | Up 39.1% |
| Shareholders' equity | 5.66bn | 6.09bn | Up 7.6% |
Questions people ask
Did Biomarin Pharmaceutical Inc's revenue grow last year?
Revenue grew 12.9%, from USD 2.85bn to USD 3.22bn in the year ended 31 Dec 2025.
Is Biomarin Pharmaceutical Inc profitable?
Yes. Net income was USD 348.90m in the year ended 31 Dec 2025. The year before: USD 426.86m.
How much cash and debt does Biomarin Pharmaceutical Inc have?
At its latest year end (31 Dec 2025), Biomarin Pharmaceutical Inc reported cash and cash equivalents of USD 1.31bn.
Where do these numbers come from?
From Biomarin Pharmaceutical Inc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Biomarin Pharmaceutical Inc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%